NEUSTAR
Threat data feeds can help organisations strengthen their cybersecurity posture, according to a new report from Ponemon Institute, the pre-eminent research centre dedicated to privacy, data protection and information security policy. Neustar Inc. , a global information services and technology company and leader in identity resolution, sponsored the independently conducted study on the state of threat feed effectiveness in the United States and the United Kingdom.
As cyberthreats proliferate, many organisations are using threat feeds with insights from domain name system (DNS) data to help IT security teams better understand threats and block malicious activity. A large majority (79%) of the more than 1,000 security professionals participating in the Ponemon study said threat data feeds were essential to their organisation’s ability to achieve a strong cybersecurity posture, and more than half (55%) rate the quality of their threat feeds’ ability to pinpoint cyberthreats as very high.
Study participants said threat data feeds offer a number of benefits: they add unique data to better inform security (71%), increase preventive blocking to ensure a better defence (63%), reduce the mean time to detect and remediate an attack (55%), and reduce the time spent researching false positives (51%).
However, more than half (56%) of respondents also said threat feeds deliver data that is often too voluminous and/or complex to provide timely and actionable intelligence.
Neustar’s UltraThreat Feeds service addresses these issues by drawing on proprietary data derived from the company’s expansive authoritative and recursive DNS services, DDoS mitigation solutions, OneID system and IP geolocation data. This service, which processes the data and outputs the observations and key insights, has been designed by Neustar’s renowned DNS experts, as well as leading academic researchers. UltraThreat Feeds data, provided as either near real-time threat data feeds or via API calls (JSON format), enable organisations to detect potential threats and identify and stop bad traffic, both inbound and outbound.
“Facing an increase in the volume, sophistication and diversity of threats, enterprises are investing significant resources into threat intelligence solutions to bolster their cyber defences,” said Michael Kaczmarek, senior vice president at Neustar. “Solutions that deliver real-time information on active threats, like Neustar’s UltraThreat Feeds service, can quickly deliver ROI across many layers of an organisation’s defence by improving the performance of network and application security tools – such as SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls – which require threat data to effectively detect and block malicious actors.”
Each of the organisations surveyed by Ponemon faced an average of 28 cyberattacks in the past two years. On average, respondents said 38% of these cyberattacks were not stopped because security teams lacked timely and actionable data from their data feeds. Respondents also reported that half (50%) of all attacks can be stopped using timely and actionable intelligence from their threat feeds.
“The deep, rich threat data delivered by Neustar’s UltraThreat Feeds service empowers users to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks,” added Kaczmarek.
The Ponemon report is based on survey responses from 1,025 IT security practitioners (70% of whom were at or above the supervisory level) in the U.S. and the U.K. whose organisations use threat data in their cybersecurity programmes or infrastructure. The most-represented industry was financial services (18% of respondents), followed by industrial and manufacturing (12%), retail (11%), public sector (11%), and health and pharmaceuticals (9%). Just over half of the participants were from organisations with a global headcount of more than 5,000 employees. The surveys were carried out in November 2020.
To access the full report, go to https://www.home.neustar/resources/whitepapers/state-of-threat-feed-effectiveness .
For more information about Neustar’s UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultrathreat-feeds . To learn more about Neustar’s full suite of security solutions, visit https://www.home.neustar/security-solutions .
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enable trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in marketing, risk, communications and security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
